CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Editas Medicine - EDIT CFD

9.42
5.33%
0.07
Low: 9.42
High: 9.98
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 9.95
Open* 9.98
1-Year Change* -68.63%
Day's Range* 9.42 - 9.42
52 wk Range 9.59-34.27
Average Volume (10 days) 2.04921
Average Volume (3 months) 33.6896
Market Cap 719.261
P/E Ratio N/A
Shares Outstanding 68763000
Revenue 25.644
EPS -2.93317
Dividend (Yield %) N/A
Beta 1.90874
Next Earnings Date Feb 22, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 9, 2022 9.42 -0.40 -4.07% 9.82 9.98 9.39
Dec 8, 2022 9.95 0.04 0.40% 9.91 10.22 9.69
Dec 7, 2022 9.88 0.50 5.33% 9.38 10.00 9.20
Dec 6, 2022 9.59 -0.09 -0.93% 9.68 10.43 9.47
Dec 5, 2022 9.80 -0.19 -1.90% 9.99 10.22 9.73
Dec 2, 2022 10.24 0.51 5.24% 9.73 10.30 9.68
Dec 1, 2022 10.03 -0.40 -3.84% 10.43 10.59 9.88
Nov 30, 2022 10.55 0.79 8.09% 9.76 10.58 9.61
Nov 29, 2022 9.91 0.08 0.81% 9.83 10.03 9.69
Nov 28, 2022 9.83 -0.03 -0.30% 9.86 10.04 9.72
Nov 25, 2022 10.00 -0.10 -0.99% 10.10 10.24 9.94
Nov 23, 2022 10.32 0.01 0.10% 10.31 10.69 10.27
Nov 22, 2022 10.43 0.26 2.56% 10.17 10.45 9.97
Nov 21, 2022 10.24 -0.51 -4.74% 10.75 10.75 10.07
Nov 18, 2022 10.92 0.34 3.21% 10.58 10.94 10.40
Nov 17, 2022 10.97 1.10 11.14% 9.87 10.99 9.57
Nov 16, 2022 12.20 -0.60 -4.69% 12.80 12.93 12.19
Nov 15, 2022 13.02 -0.36 -2.69% 13.38 13.87 12.74
Nov 14, 2022 12.90 0.13 1.02% 12.77 13.26 12.77
Nov 11, 2022 13.19 1.14 9.46% 12.05 13.46 12.05

Editas Medicine Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 6.053 13.728 31.937 20.531 90.732 25.544
Revenue 6.053 13.728 31.937 20.531 90.732 25.544
Total Operating Expense 103.241 133.661 145.664 161.453 225.572 218.69
Selling/General/Admin. Expenses, Total 46.262 50.502 55.01 64.555 67.576 76.183
Research & Development 56.979 83.159 90.654 96.898 157.996 142.507
Operating Income -97.188 -119.933 -113.727 -140.922 -134.84 -193.146
Interest Income (Expense), Net Non-Operating 0.062 -0.978 3.445 7.313 2.605 2.342
Other, Net -0.057 0.587 0.328 -0.137 16.259 -1.698
Net Income Before Taxes -97.183 -120.324 -109.954 -133.746 -115.976 -192.502
Net Income After Taxes -97.183 -120.324 -109.954 -133.746 -115.976 -192.502
Net Income Before Extra. Items -97.183 -120.324 -109.954 -133.746 -115.976 -192.502
Net Income -97.183 -120.324 -109.954 -133.746 -115.976 -192.502
Total Adjustments to Net Income -0.047 0 0
Income Available to Common Excl. Extra. Items -97.23 -120.324 -109.954 -133.746 -115.976 -192.502
Income Available to Common Incl. Extra. Items -97.23 -120.324 -109.954 -133.746 -115.976 -192.502
Diluted Net Income -97.23 -120.324 -109.954 -133.746 -115.976 -192.502
Diluted Weighted Average Shares 32.2197 40.3236 47.0977 49.9833 58.6094 67.6194
Diluted EPS Excluding Extraordinary Items -3.01772 -2.98396 -2.33459 -2.67581 -1.9788 -2.84685
Diluted Normalized EPS -3.01772 -2.98396 -2.33459 -2.67581 -1.9788 -2.84685
Total Extraordinary Items 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 6.499 0.379 6.197 12.469 6.771
Revenue 6.499 0.379 6.197 12.469 6.771
Total Operating Expense 63.382 55.78 45.45 54.079 57.521
Selling/General/Admin. Expenses, Total 21.445 22.027 16.185 16.526 19.545
Research & Development 41.937 33.753 29.265 37.553 37.976
Operating Income -56.883 -55.401 -39.253 -41.61 -50.75
Interest Income (Expense), Net Non-Operating 0.134 0.146 0.152 1.91 0.469
Other, Net 0.021 -0.001 0.019 -1.736 -0.234
Net Income Before Taxes -56.728 -55.256 -39.082 -41.436 -50.515
Net Income After Taxes -56.728 -55.256 -39.082 -41.436 -50.515
Net Income Before Extra. Items -56.728 -55.256 -39.082 -41.436 -50.515
Net Income -56.728 -55.256 -39.082 -41.436 -50.515
Income Available to Common Excl. Extra. Items -56.728 -55.256 -39.082 -41.436 -50.515
Income Available to Common Incl. Extra. Items -56.728 -55.256 -39.082 -41.436 -50.515
Diluted Net Income -56.728 -55.256 -39.082 -41.436 -50.515
Diluted Weighted Average Shares 65.9924 67.8771 68.2197 68.3638 68.485
Diluted EPS Excluding Extraordinary Items -0.85961 -0.81406 -0.57288 -0.60611 -0.73761
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.85961 -0.81406 -0.57288 -0.60611 -0.73761
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 187.183 332.199 374.776 463.844 419.087 507.31
Cash and Short Term Investments 185.323 329.139 368.955 457.14 402.11 499.845
Cash & Equivalents 185.323 146.63 134.776 238.183 139.682 203.519
Total Receivables, Net 0.088 0.679 0.03 0.418 6.048 0.267
Accounts Receivable - Trade, Net 0.088 0.679 0.03 0.418 6.048 0.267
Prepaid Expenses 1.662 1.864 2.918 6.286 10.929 7.198
Other Current Assets, Total 0.11 0.517 2.873
Total Assets 229.182 373.26 420.386 508.885 572.602 677.483
Property/Plant/Equipment, Total - Net 40.378 39.442 40.232 39.648 39.148 43.291
Property/Plant/Equipment, Total - Gross 41.934 43.5 47.365 46.852 50.243 58.798
Accumulated Depreciation, Total -1.556 -4.058 -7.133 -7.204 -11.095 -15.507
Other Long Term Assets, Total 1.621 1.619 5.378 5.393 4.703 6.811
Total Current Liabilities 33.083 36.707 35.9 59.963 58.208 46.884
Accounts Payable 4.64 4.02 5.327 5.843 6.408 5.05
Accrued Expenses 17.439 11.049 12.813 27.924 30.857 30.501
Notes Payable/Short Term Debt 10 7.5 0 0 0 0
Other Current Liabilities, Total 1.004 14.138 17.76 26.196 20.943 11.333
Total Liabilities 94.575 165.18 184.224 246.448 179.016 123.841
Total Long Term Debt 35.096 33.431 32.417 0 0 0
Capital Lease Obligations 35.096 33.431 32.417 0
Other Liabilities, Total 26.396 95.042 115.907 186.485 120.808 76.957
Total Equity 134.607 208.08 236.162 262.437 393.586 553.642
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.004 0.004 0.005 0.005 0.006 0.007
Additional Paid-In Capital 320.129 514.002 652.464 811.546 1058.82 1411.83
Retained Earnings (Accumulated Deficit) -185.526 -305.85 -416.278 -549.221 -665.197 -857.699
Total Liabilities & Shareholders’ Equity 229.182 373.26 420.386 508.885 572.602 677.483
Total Common Shares Outstanding 35.8181 44.508 48.7589 54.5538 62.5635 68.4353
Short Term Investments 182.509 234.179 218.957 262.428 296.326
Other Equity, Total -0.076 -0.029 0.107 -0.046 -0.493
Long Term Investments 109.664 120.071
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 632.316 616.292 567.608 507.31 497.031
Cash and Short Term Investments 625.333 610.553 557.841 499.845 488.362
Cash & Equivalents 354.918 337.834 259.884 203.519 210.881
Short Term Investments 270.415 272.719 297.957 296.326 277.481
Total Receivables, Net 0.672 0.331 0.251 0.267 1.371
Accounts Receivable - Trade, Net 0.672 0.331 0.251 0.267 1.371
Prepaid Expenses 6.311 5.408 9.516 7.198 7.298
Total Assets 780.294 755.88 717.019 677.483 623.108
Property/Plant/Equipment, Total - Net 43.4 45.224 43.432 43.291 40.715
Property/Plant/Equipment, Total - Gross 55.388 58.4 57.475 58.798 57.779
Accumulated Depreciation, Total -11.988 -13.176 -14.043 -15.507 -17.064
Long Term Investments 97.89 87.584 99.198 120.071 78.046
Other Long Term Assets, Total 6.688 6.78 6.781 6.811 7.316
Total Current Liabilities 64.01 66.016 50.907 46.884 36.503
Accounts Payable 8.91 4.415 3.402 5.05 4.693
Accrued Expenses 22.396 27.601 24.838 30.501 25.993
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 32.704 34 22.667 11.333 5.817
Total Liabilities 142.298 142.519 130.225 123.841 110.348
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 78.288 76.503 79.318 76.957 73.845
Total Equity 637.996 613.361 586.794 553.642 512.76
Common Stock 0.007 0.007 0.007 0.007 0.007
Additional Paid-In Capital 1359.99 1390.61 1403.11 1411.83 1423.48
Retained Earnings (Accumulated Deficit) -721.925 -777.181 -816.263 -857.699 -908.214
Other Equity, Total -0.073 -0.071 -0.064 -0.493 -2.509
Total Liabilities & Shareholders’ Equity 780.294 755.88 717.019 677.483 623.108
Total Common Shares Outstanding 67.4726 68.1598 68.3207 68.4353 68.6027
Redeemable Preferred Stock 0 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -97.183 -120.324 -109.954 -133.746 -115.976 -192.502
Cash From Operating Activities -50.246 -9.417 -45.707 -40.669 -179.843 -163.803
Cash From Operating Activities 1.202 2.683 3.254 2.83 3.959 5.053
Non-Cash Items 27.837 37.564 34.105 24.315 34.394 45.056
Cash Interest Paid 0.465 0.013
Changes in Working Capital 17.898 70.66 26.888 65.932 -102.22 -21.41
Cash From Investing Activities -3.473 -183.81 -53.087 12.252 -140.522 -54.466
Capital Expenditures -3.493 -2.059 -4.754 -6.167 -7.162 -7.977
Other Investing Cash Flow Items, Total 0.02 -181.751 -48.333 18.419 -133.36 -46.489
Cash From Financing Activities 97.161 154.534 86.94 131.824 224.122 282.106
Financing Cash Flow Items 0 0
Issuance (Retirement) of Stock, Net 97.721 155.898 87.797 131.824 224.122 282.106
Issuance (Retirement) of Debt, Net -0.56 -1.364 -0.857 0
Net Change in Cash 43.442 -38.693 -11.854 103.407 -96.243 63.837
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -56.728 -111.984 -151.066 -192.502 -50.515
Cash From Operating Activities -49.479 -88.436 -129.221 -163.803 -49.227
Cash From Operating Activities 1.163 2.352 3.542 5.053 1.558
Non-Cash Items 12.605 26.64 37.074 45.056 11.665
Changes in Working Capital -6.519 -5.444 -18.771 -21.41 -11.935
Cash From Investing Activities 3.244 8.035 -31.626 -54.466 56.371
Capital Expenditures -0.084 -2.788 -5.132 -7.977 -2.248
Other Investing Cash Flow Items, Total 3.328 10.823 -26.494 -46.489 58.619
Cash From Financing Activities 261.471 278.553 281.049 282.106 0.218
Issuance (Retirement) of Stock, Net 261.471 278.553 281.049 282.106 0.218
Net Change in Cash 215.236 198.152 120.202 63.837 7.362
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.7634 6713593 89730 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 9.2329 6348781 -1531109 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 7.8836 5420965 69877 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 3.0301 2083555 413759 2022-09-30 HIGH
Millennium Management LLC Hedge Fund 2.7382 1882870 1731710 2022-09-30 HIGH
PFM Health Sciences, LP Hedge Fund 1.8601 1279054 649370 2022-09-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8273 1256520 29890 2022-09-30 LOW
Capital World Investors Investment Advisor 1.5997 1100000 0 2022-09-30 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.5873 1091469 -45937 2022-09-30 LOW
Credit Suisse Asset Management Investment Advisor/Hedge Fund 1.4212 977260 2219 2022-09-30 LOW
Citadel Advisors LLC Hedge Fund 1.3014 894871 -362299 2022-09-30 HIGH
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.2398 852506 171124 2022-09-30 LOW
Goldman Sachs & Company, Inc. Research Firm 1.0253 705030 88575 2022-09-30 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.9547 656502 -38556 2022-09-30 LOW
Morgan Stanley & Co. LLC Research Firm 0.8822 606601 -133499 2022-09-30 MED
Nuveen LLC Pension Fund 0.8489 583747 -2153 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.8383 576441 3135 2022-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.7263 499456 12628 2022-09-30 LOW
Capital Fund Management S.A. Hedge Fund 0.7196 494850 116188 2022-09-30 HIGH
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.7135 490627 46798 2021-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
480000+

Traders

75000+

Active clients monthly

$52000000+

Monthly investing volume

$34000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Editas Medicine Company profile

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry: Biotechnology & Medical Research (NEC)

11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US

Income Statement

People also watch

BTC/USD

17,178.85 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

11,547.10 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 3.0

XRP/USD

0.39 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00323

Oil - Crude

71.65 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee -0.0013%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading